Advance More Personalized & Efficacious Therapies to Transform the Standard of Care for Rare & Common Kidney Diseases
Uniting Renal Biotech & Pharma to Drive the Next Wave of CKD Drug Discovery, Translation & Clinical Innovation
With recent FDA approvals for Apellis’ pegcetacoplan for C3G and Novartis’ atrasentan for IgAN, the renal drug development space is entering a transformative era. Over 75 biopharma companies and over 80 pipeline drugs, including AstraZeneca, Eli Lilly, Boehringer Ingelheim, and Bayer, are doubling down on CKD R&D, driven by transcriptomic breakthroughs, novel endpoints like proteinuria and eGFR, and a surge in precision medicine strategies. The global CKD market is projected to exceed $110 billion by 2030, with landmark deals such as Novartis’ $1.7B acquisition of Regulus Therapeutics underscoring the sector’s momentum.
Returning to Boston on March 16–18, 2026, the 8th CKD Drug Development Summit unites 150+ senior leaders across discovery, translational, clinical, regulatory, and commercial functions. Hear from 44+ expert speakers from over 35+ companies including Apellis Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Eli Lilly, Maze Therapeutics, Otsuka, Purespring Therapeutics, Takeda, Vertex Pharmaceuticals, and more. With dedicated tracks for preclinical and clinical innovation, plus a brand-new Polycystic Kidney Disease Focus Day and late-stage workshops on regulatory strategy and market access, the summit delivers three days of cutting-edge insights, strategic networking, and actionable takeaways to accelerate renal therapeutic innovation.
The CKD Summit assembles a great panel and attendees from both academia and industry in a setting that fosters 1:1 interactions and deep discussion into science and how best to advance projects. The vendors who also attend provide great value and new ideas for projects/technologies.
Shawn Badal, Director, Kidney Discovery Research, Eli Lilly
The CKD Summit brings together experienced professionals and thought leaders in chronic kidney disease to share high-impact insights and cutting-edge developments. With a strong focus on CKD, the Summit offers exceptional opportunities for scientific exchange, strategic collaboration, and meaningful networking across the kidney health community.
Jennifer McKenzie, Senior Clinical Program Leader in CRM, Boehringer Ingelheim
The conference is a great opportunity to connect and learn from peers and experts in CKD and to share and advance our knowledge in the pursuit of better treatments.
Ginny Collins, Senior Director, Regulatory Affairs, Apellis Pharmaceuticals
Explore the Full Event Guide
- 150+ Global Attendees from Across the Renal Landscape
- 45+ World Class Speakers with Unique Insights
- 35+ Speaking Companies
- 10+ Hours of Face-to-Face Networking Opportunities
- 3 Days of Unmissable Data-Driven Content
- 2 Dedicated Tracks of Content for the Whole Team
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into 2 tracks, 1 Polycystic Kidney Focus Day, 2 Regulatory & Access Workshops and 44+ expert speakers shaping the future of CKD
Partner With Us
Showcase your solutions, connect with decision makers, and position your company as the go-to provider in precision oncology
Join Biopharma Experts
Network with pharma, biotech, diagnostics, academia, consortia, and patient voices driving real-world adoption